<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002474</url>
  </required_header>
  <id_info>
    <org_study_id>LUMC-3007</org_study_id>
    <secondary_id>CDR0000076845</secondary_id>
    <secondary_id>NCI-V91-0058</secondary_id>
    <nct_id>NCT00002474</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Refractory or Recurrent Ovarian Cancer</brief_title>
  <official_title>Phase II Study of High Dose Cyclophosphamide, Mitoxantrone, and Carboplatin With Autologous Bone Marrow Transplantation in Refractory or Relapsed Ovarian Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loyola University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, carboplatin, and&#xD;
      mitoxantrone, work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells or by stopping them from dividing. Giving chemotherapy with autologous bone marrow&#xD;
      transplant may allow the doctor to give higher doses of chemotherapy and kill more tumor&#xD;
      cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well chemotherapy and autologous bone marrow&#xD;
      transplant work in treating patients with refractory or recurrent ovarian cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the response rate, duration of response, and overall survival of patients with&#xD;
           refractory or relapsed ovarian epithelial cancer treated with high-dose&#xD;
           cyclophosphamide, carboplatin, and mitoxantrone followed by autologous bone marrow&#xD;
           transplantation.&#xD;
&#xD;
        -  Determine the nonhematopoietic toxicity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: Autologous bone marrow is harvested before study entry. Patients receive high-dose&#xD;
      cyclophosphamide IV over 1 hour and mitoxantrone IV over 15 minutes on days -8, -6, and -4&#xD;
      and carboplatin IV continuously on days -8 to -3 in the absence of unacceptable toxicity.&#xD;
      Bone marrow is reinfused on day 0 beginning at least 60 hours after completion of carboplatin&#xD;
      infusion.&#xD;
&#xD;
      Patients are followed for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 15-30 patients will be accrued for this study within 1.5-3&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1991</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Response duration</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Nonhematopoietic toxicity</measure>
  </primary_outcome>
  <condition>Ovarian Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitoxantrone hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone marrow ablation with stem cell support</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of refractory or relapsed ovarian epithelial cancer&#xD;
&#xD;
               -  Must have failed prior regimen containing cisplatin or carboplatin&#xD;
&#xD;
          -  Bidimensionally measurable or evaluable disease&#xD;
&#xD;
               -  Serial CA-125 antigen titers or cytologically positive pleural effusion and/or&#xD;
                  ascites acceptable as evaluable disease&#xD;
&#xD;
          -  Autologous bone marrow harvest of greater than 1.2 x 10 to the eighth nucleated&#xD;
             cells/kg required before study entry&#xD;
&#xD;
          -  No evidence of tumor at marrow harvest sites by bilateral bone marrow aspirates and&#xD;
             biopsies, pelvic x-ray, and bone scan&#xD;
&#xD;
          -  CNS involvement allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Under 65&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  SWOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 8 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC greater than 3,500/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 10.0 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL&#xD;
&#xD;
          -  SGOT and SGPT less than 2 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
          -  No prior hemorrhagic cystitis&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  LVEF greater than 45% by MUGA scan&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No hearing loss in voice tones&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No psychological contraindication to study treatment&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  General medical condition must allow general anesthesia&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior bone marrow transplantation&#xD;
&#xD;
          -  More than 4 weeks since other prior biologic therapy and recovered&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (at least 6 weeks for nitrosoureas or&#xD;
             mitomycin) and recovered&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick J. Stiff, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Loyola University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardinal Bernardin Cancer Center at Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153-5500</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Stiff PJ, Bayer R, Kerger C, Potkul RK, Malhotra D, Peace DJ, Smith D, Fisher SG. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol. 1997 Apr;15(4):1309-17. doi: 10.1200/JCO.1997.15.4.1309.</citation>
    <PMID>9193322</PMID>
  </results_reference>
  <results_reference>
    <citation>Stiff P, Bayer R, Camarda M, Tan S, Dolan J, Potkul R, Loutfi S, Kinch L, Sosman J, Peace D, et al. A phase II trial of high-dose mitoxantrone, carboplatin, and cyclophosphamide with autologous bone marrow rescue for recurrent epithelial ovarian carcinoma: analysis of risk factors for clinical outcome. Gynecol Oncol. 1995 Jun;57(3):278-85. doi: 10.1006/gyno.1995.1143.</citation>
    <PMID>7774830</PMID>
  </results_reference>
  <verification_date>March 2003</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>May 29, 2013</last_update_submitted>
  <last_update_submitted_qc>May 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2013</last_update_posted>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

